Kevin H M Kuo

List of Publications by Year
in descending order

58	696	758635 12	580395 25
papers	citations	h-index	g-index

58	58	58	946
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency. New England Journal of Medicine, 2019, 381, 933-944.	13.9	115
2	Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis. Blood, 2015, 126, 2424-2435.	0.6	81
3	Genotypeâ€phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, 472-482.	2.0	47
4	Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics. Transfusion Medicine Reviews, 2019, 33, 256-265.	0.9	46
5	A comparison of chronic manual and automated red blood cell exchange transfusion in sickle cell disease patients. British Journal of Haematology, 2015, 170, 425-428.	1.2	38
6	A Systematic Review and Meta-Analysis of Deferiprone Monotherapy and in Combination with Deferoxamine for Reduction of Iron Overload in Chronically Transfused Patients with Î²-Thalassemia. Hemoglobin, 2014, 38, 409-421.	0.4	37
7	A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis. British Journal of Haematology, 2015, 168, 384-394.	1.2	36
8	Impact of a transition program with navigator on loss to followâ€up, medication adherence, and appointment attendance in hemoglobinopathies. Pediatric Blood and Cancer, 2019, 66, e27781.	0.8	33
9	The variable manifestations of disease in pyruvate kinase deficiency and their management. Haematologica, 2020, 105, 2229-2239.	1.7	30
10	Comorbidities and complications in adults with pyruvate kinase deficiency. European Journal of Haematology, 2021, 106, 484-492.	1.1	17
11	The pyruvate kinase (PK) to hexokinase enzyme activity ratio andÂerythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. British Journal of Haematology, 2021, 192, 1092-1096.	1.2	15
12	Deferiprone exerts a doseâ€dependent reduction of liver iron in adults with iron overload. European Journal of Haematology, 2019, 103, 80-87.	1.1	14
13	The International Hemoglobinopathy Research Network (<scp>INHERENT</scp>): An international initiative to study the role of genetic modifiers in hemoglobinopathies. American Journal of Hematology, 2021, 96, E416-E420.	2.0	14
14	Extracorporeal photopheresis in solid organ transplantâ€“associated acute graftâ€versusâ€host disease. Transfusion, 2016, 56, 962-969.	0.8	12
15	Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. Blood Advances, 2022, 6, 1844-1853.	2.5	12
16	Multiple Testing in the Context of Gene Discovery in Sickle Cell Disease Using Genome-Wide Association Studies. Genomics Insights, 2017, 10, 117863101772117.	3.0	11
17	A proposed treatment algorithm for adults with Haemoglobin <scp>SC</scp> disease. British Journal of Haematology, 2018, 182, 607-609.	1.2	11
18	The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 163-163.	0.6	11

#	Article	IF	Citations
19	Safety and pharmacokinetics of the oral iron chelator SPâ€420 in Î²â€thalassemia. American Journal of Hematology, 2017, 92, 1356-1361.	2.0	10
20	Distinct maternal and fetal pregnancy outcomes in women with sickle cell disease can be predicted using routine clinical and laboratory data. British Journal of Haematology, 2021, 194, 1063-1073.	1.2	10
21	Characterization of the severe phenotype of pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, E281.	2.0	8
22	Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in Î²-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial. Blood, 2020, 136, 45-46.	0.6	8
23	Screening for Cognitive Dysfunction Using the Rowland Universal Dementia Assessment Scale in Adults With Sickle Cell Disease. JAMA Network Open, 2021, 4, e217039.	2.8	7
24	Management of Hyperleukocytosis in Acute Myelogenous Leukemia Using Hydroxyurea Rather Than Leukopheresis.. Blood, 2006, 108, 2007-2007.	0.6	7
25	Optimal Manual Exchange Transfusion Protocol for Sickle Cell Disease: A Retrospective Comparison of Two Comprehensive Care Centers in the United Kingdom and Canada. Hemoglobin, 2015, 39, 310-315.	0.4	5
26	Comparison of Inline R2* MRI versus FerriScan for liver iron quantification in patients on chelation therapy for iron overload: preliminary results. European Radiology, 2021, 31, 9296-9305.	2.3	5
27	Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study. Blood, 2016, 128, 402-402.	0.6	5
28	Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia. Blood, 2021, 138, 576-576.	0.6	5
29	Impact of MRI technique on clinical decision-making in patients with liver iron overload: comparison of FerriScan- versus R2*-derived liver iron concentration. European Radiology, 2020, 30, 1959-1968.	2.3	4
30	Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study. Journal of Clinical Medicine, 2022, 11, 1193.	1.0	4
31	Approach to transfusion in pregnant women with sickle cell disease: a survey of physicians. British Journal of Haematology, 2018, 183, 516-519.	1.2	3
32	Cord gas parameters in infants born to women with sickle cell disease: a retrospective matched cohort study. British Journal of Haematology, 2019, 184, 653-657.	1.2	3
33	Mitapivat Improves Ineffective Erythropoiesis and Reduces Iron Overload in Patients with Pyruvate Kinase Deficiency. Blood, 2021, 138, 2005-2005.	0.6	3
34	Bone Mineral Density Remains Stable in Pyruvate Kinase Deficiency Patients Receiving Long-Term Treatment with Mitapivat. Blood, 2021, 138, 924-924.	0.6	3
35	Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency. Blood, 2020, 136, 30-32.	0.6	3
36	Assessing Cerebrovascular Resistance in Patients With Sickle Cell Disease. Frontiers in Physiology, 2022, 13, 847969.	1.3	3

#	Article	IF	Citations
37	EspP, an Extracellular Serine Protease from Enterohemorrhagic E. coli, Reduces Coagulation Factor Activities, Reduces Clot Strength, and Promotes Clot Lysis. PLoS ONE, 2016, 11, e0149830.	1.1	2
38	Management of Polycythemia Vera: A Survey of Canadian Physician Practice Patterns. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e37-e42.	0.2	2
39	Novel High Oxygen Affinity Hemoglobin Variant in a Patient with Polycythemia: Hb Kennisis [Î²85(F1)Pheâ†'Leu (TTT>TTG); HBB: c.258T>G]. Hemoglobin, 2020, 44, 10-12.	0.4	2
40	Evidence of Educational Bias in Cognitive Screening of Adults with Sickle Cell Disease: Comparison of Available Tools and Possible Strategies for Mitigation. Blood, 2020, 136, 13-14.	0.6	2
41	A Comparison of Automated Red Blood Cell Depletion/Exchange to Automated Red Cell Blood Exchange in Sickle Cell Patients.. Blood, 2012, 120, 2281-2281.	0.6	2
42	A North American Experience Of Hemoglobin SC Disease, Its Complications, and Management. Blood, 2013, 122, 2221-2221.	0.6	2
43	A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Mitapivat in Patients with Sickle Cell Disease. Blood, 2021, 138, 3109-3109.	0.6	2
44	Sickle Cell Cerebrovascular Reactivity to a CO2 Stimulus Is Both Too Little and Too Slow. Blood, 2020, 136, 55-55.	0.6	1
45	A Comparison of Chronic Manual and Automated Red Blood Cell Exchange Transfusion in Sickle Cell Disease Patients From Two Comprehensive Care Centres in the United Kingdom. Blood, 2012, 120, 3430-3430.	0.6	1
46	Treatment Patterns and Outcomes Of Sickle Cell Patients With Frequent ER Visits: A Single Center Experience. Blood, 2013, 122, 1010-1010.	0.6	1
47	Effectiveness Of An Analgesia Protocol For The Treatment Of Painful Vaso-Occlusive Crisis Of Sickle Cell Disease Patients In Emergency Room: A Retrospective Cohort Study. Blood, 2013, 122, 2222-2222.	0.6	1
48	Cognitive Profile of Adults with Sickle Cell Disease - Cluster Analysis. Blood, 2021, 138, 3120-3120.	0.6	1
49	Use of Thromboprophylaxis for Central Venous Access Devices in Patients with Sickle Cell Disease: A Survey of Canadian Providers. Blood, 2021, 138, 4173-4173.	0.6	1
50	Adverse outcome of acute splenic sequestration crisis in pregnancy. Obstetric Medicine, 2021, 14, 113-115.	0.5	0
51	The Effect of Comprehensive Care on Maternal and Fetal Outcomes in Sickle Cell Disease Pregnancies. Blood, 2011, 118, 4842-4842.	0.6	0
52	Characterization Of Pulmonary Compliance In Sickle Cell Patients Revealed Wide Variability. Blood, 2013, 122, 989-989.	0.6	0
53	Should Women with Sickle Cell Disease be Administered Prophylactic Transfusions to Avoid Complications during Pregnancy?. Blood, 2018, 132, 3679-3679.	0.6	0
54	Validation of Sickle Cell Disease Severity Score in a Cohort of Hemoglobin SC Disease Patients. Blood, 2018, 132, 2287-2287.	0.6	0

#	Article	IF	Citations
55	Patient Education Interventions for Improving Self-Management in Adults with Hemoglobinopathies: A Systematic Review and Meta-Analysis. Blood, 2019, 134, 5783-5783.	0.6	0
56	Characterizing Iron Overload By Age in Patients Diagnosed with Pyruvate Kinase Deficiency - a Descriptive Analysis from the Peak Registry. Blood, 2021, 138, 3074-3074.	0.6	0
57	Characterizing the Process of Urgent Referrals and Transfers to a Large Tertiary Care Apheresis Centre in Ontario. Blood, 2020, 136, 28-28.	0.6	0
58	Allogeneic Hematopoietic Stem Cell Transplant Versus Gene Therapy in Sickle Cell Disease: Updated Results from a Systematic Review. Blood, 2020, 136, 11-12.	0.6	0